Articular cartilage regeneration with microfracture and hyaluronic acid.

Department of Chemical Engineering, Hanyang University, Seoul, Korea.
Biotechnology Letters (Impact Factor: 1.74). 04/2008; 30(3):435-9. DOI: 10.1007/s10529-007-9576-2
Source: PubMed

ABSTRACT Microfracture used to treat articular cartilage injuries can facilitate access to stem cells in the bone marrow and stimulate cartilage regeneration. However, the regenerated cartilage is fibrocartilage as opposed to hyaline articular cartilage and is thinner than native cartilage. Following microfracture in rabbit knee cartilage defects, application of hyaluronic acid gel resulted in regeneration of a thicker, more hyaline-like cartilage. The addition of transforming growth factor-beta3, an inducer of chondrogenic differentiation in mesenchymal stem cells, to the treatment with microfracture and hyaluronic acid did not significantly benefit cartilage regeneration.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Bone marrow stimulation techniques (BSTs) are widely used in clinics to treat cartilage defects, but yet have a critical limitation from the loss of blood clots. In this work, a novel cartilage extracellular matrix (CECM) membrane is developed to protect blood clots after BSTs. The CECM membrane was made of ECM fabricated naturally by cultured porcine chondrocytes, and then decellularized and multi-layered to confer optimal mechanical strength. Highly compatible with cells, the CECM membrane did not show any cytotoxicity or immune responses in vivo. The CECM membrane was very thin (30–60 μm thick) and bendable, but had good tensile strength (85.64 N), suitable for protecting blood clots from leakage in rabbit cartilage defect. Moreover, the CECM membrane showed low but enough diffusion coefficient to allow delivery of small proteins in synovial fluid into the repaired tissue. In a beagle model, covering the cartilage defect with the CECM membrane after BST generated more hyaline cartilage-like tissues than the BST alone in histology and chemical analyses at 18 weeks. Its ICRS score was approximately 2.5 times higher than that of the BST alone. Therefore, the CECM membrane is proposed as a useful tool that can improve the outcome of BSTs to treat cartilage defects.
    Advanced Functional Materials 10/2012; 22(20). DOI:10.1002/adfm.201102695 · 10.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In cartilage regeneration, bio-activated implants are used in stem and progenitor cell-based microfracture cartilage repair procedures. Our aim was to analyze the chondrogenic potential of freeze-dried resorbable polymer-based polyglycolic acid (PGA) scaffolds bio-activated with transforming growth factor-β3 (TGFB3) on human subchondral mesenchymal progenitor cells known from microfracture. Progenitor cells derived from femur heads were cultured in the presence of freeze-dried TGFB3 in high-density pellet culture and in freeze-dried TGFB3-PGA scaffolds for chondrogenic differentiation. Progenitor cell cultures in PGA scaffolds as well as pellet cultures with and without continuous application of TGFB3 served as controls. Release studies showed that freeze-dried TGFB3-PGA scaffolds facilitate a rapid, initial boost-like release of 71.5% of TGFB3 in the first 10 h. Gene expression analysis and histology showed induction of typical chondrogenic markers like type II collagen and formation of cartilaginous tissue in TGFB3-PGA scaffolds seeded with subchondral progenitor cells and in pellet cultures stimulated with freeze-dried TGFB3. Chondrogenic differentiation in freeze-dried TGFB3-PGA scaffolds was comparable to cultures receiving TGFB3 continuously, while non-stimulated controls did not show chondrogenesis during prolonged culture for 14 days. These results suggest that bio-activated, freeze-dried TGFB3-PGA scaffolds have chondrogenic potential and are a promising tool for stem cell-mediated cartilage regeneration.
    Annals of Biomedical Engineering 08/2014; DOI:10.1007/s10439-014-1099-0 · 3.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Marrow stimulation is frequently employed to treat focal chondral defects of the knee. However, marrow stimulation typically results in fibrocartilage repair tissue rather than healthy hyaline cartilage, which, over time, predisposes the repair to failure. Recently, a cryopreserved viable chondral allograft was developed to augment marrow stimulation. The chondral allograft is comprised of native viable chondrocytes, chondrogenic growth factors, and extracellular matrix proteins within the superficial, transitional, and radial zones of hyaline cartilage. Therefore, host mesenchymal stem cells that infiltrate the graft from the underlying bone marrow following marrow stimulation are provided with the optimal microenvironment to undergo chondrogenesis. The present report describes treatment of a trochlear defect with marrow stimulation augmented with this novel chondral allograft, along with nine month postoperative histological results. At nine months, the patient demonstrated complete resolution of pain and improvement in function, and the repair tissue consisted of 85% hyaline cartilage. For comparison, a biopsy obtained from a patient 8.2 months after treatment with marrow stimulation alone contained only 5% hyaline cartilage. These outcomes suggest that augmenting marrow stimulation with the viable chondral allograft can eliminate pain and improve outcomes, compared with marrow stimulation alone.
    01/2015; 2015:617365. DOI:10.1155/2015/617365

Similar Publications